Therapeutic methods using fusion proteins between interleukin-3 (IL-3) variants and other hematopoietic factors
US5858347A · kind A · utility
47Cited by
14References
53Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 6, 1995 |
| Grant date | Jan 12, 1999 |
| Priority date | — |
| Expiry date | Jun 6, 2015 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S930/141
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to fusion molecules composed of human interleukin-3 (hIL-3) variant or mutant proteins (muteins) functionally joined to a second colony stimulating factor (CSF), cytokine, lymphokine, interleukin or IL-3 variant. These hIL-3 variants contain amino acid substitutions and may also have amino acid deletions at both the N- and C- termini. The invention also relates to pharmaceutical compositions containing the fusion molecules and methods for using them.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.